Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis
D. C. METZ, C. W. HOWDEN, M. C. PEREZ, L. LARSEN, J. O’NEIL, S. N. ATKINSONVolume:
29
Year:
2009
Language:
english
Pages:
13
DOI:
10.1111/j.1365-2036.2009.03954.x
File:
PDF, 205 KB
english, 2009